ARCT
Price
$24.87
Change
+$0.93 (+3.88%)
Updated
Dec 1, 6:59 PM EST
85 days until earnings call
BCLI
Price
$0.26
Change
-$0.02 (-7.14%)
Updated
Dec 1, 6:59 PM EST
116 days until earnings call
Ad is loading...

ARCT vs BCLI ᐉ Comparison: Which is Better to Invest?

Header iconARCT vs BCLI Comparison
Open Charts ARCT vs BCLIBanner chart's image
Arcturus Therapeutics Holdings
Price$24.87
Change+$0.93 (+3.88%)
Volume$165.04K
CapitalizationN/A
Brainstorm Cell Therapeutics
Price$0.26
Change-$0.02 (-7.14%)
Volume$1.94M
CapitalizationN/A
View a ticker or compare two or three
ARCT vs BCLI Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
ARCT vs. BCLI commentary
Dec 04, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and BCLI is a Hold.

COMPARISON
Comparison
Dec 04, 2023
Stock price -- (ARCT: $24.87 vs. BCLI: $0.26)
Brand notoriety: ARCT and BCLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 80% vs. BCLI: 116%
Market capitalization -- ARCT: $689.46M vs. BCLI: $11.37M
ARCT [@Biotechnology] is valued at $689.46M. BCLI’s [@Biotechnology] market capitalization is $11.37M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 1 FA rating(s) are green whileBCLI’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 1 green, 4 red.
  • BCLI’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than BCLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 5 TA indicator(s) are bullish.

  • ARCT’s TA Score: 5 bullish, 6 bearish.

Price Growth

ARCT (@Biotechnology) experienced а +4.02% price change this week, while BCLI (@Biotechnology) price change was +4.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.15%. For the same industry, the average monthly price growth was +30.64%, and the average quarterly price growth was +27.15%.

Reported Earning Dates

ARCT is expected to report earnings on Feb 26, 2024.

BCLI is expected to report earnings on Mar 28, 2024.

Industries' Descriptions

@Biotechnology (+3.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ARCT with price predictions.
OPEN
A.I.dvisor published
a Summary for BCLI with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ARCT($689M) has a higher market cap than BCLI($11.4M). ARCT YTD gains are higher at: 46.639 vs. BCLI (-84.146). ARCT has higher annual earnings (EBITDA): 106M vs. BCLI (-21.28M). ARCT has more cash in the bank: 312M vs. BCLI (1.42M). BCLI has less debt than ARCT: BCLI (2.89M) vs ARCT (51.2M). ARCT has higher revenues than BCLI: ARCT (293M) vs BCLI (0).
ARCTBCLIARCT / BCLI
Capitalization689M11.4M6,044%
EBITDA106M-21.28M-498%
Gain YTD46.639-84.146-55%
P/E Ratio6.79N/A-
Revenue293M0-
Total Cash312M1.42M22,003%
Total Debt51.2M2.89M1,771%
FUNDAMENTALS RATINGS
ARCT vs BCLI: Fundamental Ratings
ARCT
BCLI
OUTLOOK RATING
1..100
1450
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
90
Overvalued
PROFIT vs RISK RATING
1..100
77100
SMR RATING
1..100
20100
PRICE GROWTH RATING
1..100
4264
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (51) in the Pharmaceuticals Major industry is somewhat better than the same rating for BCLI (90) in the Computer Peripherals industry. This means that ARCT’s stock grew somewhat faster than BCLI’s over the last 12 months.

ARCT's Profit vs Risk Rating (77) in the Pharmaceuticals Major industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that ARCT’s stock grew similarly to BCLI’s over the last 12 months.

ARCT's SMR Rating (20) in the Pharmaceuticals Major industry is significantly better than the same rating for BCLI (100) in the Computer Peripherals industry. This means that ARCT’s stock grew significantly faster than BCLI’s over the last 12 months.

ARCT's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as BCLI (64) in the Computer Peripherals industry. This means that ARCT’s stock grew similarly to BCLI’s over the last 12 months.

ARCT's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as BCLI (100) in the Computer Peripherals industry. This means that ARCT’s stock grew similarly to BCLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCT
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JMVCX15.450.26
+1.71%
Janus Henderson Mid Cap Value C
BCIFX195.841.62
+0.83%
Blue Chip Investor
FNARX41.260.30
+0.73%
Fidelity® Natural Resources Fund
MUOAX21.870.14
+0.64%
Morgan Stanley Instl US Core A
USSPX59.120.35
+0.60%
Victory 500 Index Member

BCLI and

Correlation & Price change

A.I.dvisor tells us that BCLI and MORF have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BCLI and MORF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCLI
1D Price
Change %
BCLI100%
-6.81%
MORF - BCLI
32%
Poorly correlated
+3.00%
BLRX - BCLI
30%
Poorly correlated
+4.83%
VERU - BCLI
27%
Poorly correlated
+5.75%
ARCT - BCLI
26%
Poorly correlated
+3.88%
VCNX - BCLI
24%
Poorly correlated
-15.63%
More